Glenmede Trust’s Ocular Therapeutix OCUL Stock Holding History

Glenmede Trust’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-106	Closed	–	–	1904
2020 Q3	$0	Buy	+106	New	+$880	﹤0.01%	2551

Other funds holding OCUL

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Glenmede Trust's OCUL Position: Q4 2020 in Review

Glenmede Trust sold out of Ocular Therapeutix (OCUL) in Q4 2020, closing a stake of 106 shares.

Glenmede Trust first reported a position in OCUL in Q3 2020 and held it in 1 quarter. The position peaked at $0 in Q3 2020. 149 funds tracked by Wall St. Rank hold OCUL as of Q4 2020.

Glenmede Trust reported no remaining Ocular Therapeutix position as of Q4 2020 after selling out during the quarter.
Glenmede Trust sold 106 Ocular Therapeutix shares in Q4 2020.
Glenmede Trust first reported a position in Ocular Therapeutix in Q3 2020 and held it in 1 quarter.
Glenmede Trust's Ocular Therapeutix position peaked at $0 in Q3 2020.
149 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.